BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 180 filers reported holding BRIDGEBIO PHARMA INC in Q4 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $388,958 | +53.3% | 14,750 | 0.0% | 0.01% | +75.0% |
| Q2 2023 | $253,700 | +3.7% | 14,750 | 0.0% | 0.00% | -20.0% |
| Q1 2023 | $244,555 | -26.2% | 14,750 | -66.1% | 0.01% | -28.6% |
| Q4 2022 | $331,470 | -28.7% | 43,500 | -6.9% | 0.01% | -36.4% |
| Q3 2022 | $465,000 | -1.7% | 46,737 | -10.3% | 0.01% | +10.0% |
| Q2 2022 | $473,000 | -10.6% | 52,087 | 0.0% | 0.01% | +11.1% |
| Q1 2022 | $529,000 | -39.1% | 52,087 | 0.0% | 0.01% | -40.0% |
| Q4 2021 | $869,000 | -64.5% | 52,087 | -0.4% | 0.02% | -66.7% |
| Q3 2021 | $2,451,000 | -23.1% | 52,287 | 0.0% | 0.04% | -22.4% |
| Q2 2021 | $3,187,000 | +91.4% | 52,287 | +2.4% | 0.06% | +41.5% |
| Q2 2020 | $1,665,000 | +720.2% | 51,044 | +780.1% | 0.04% | +925.0% |
| Q4 2019 | $203,000 | – | 5,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |